Trial Profile
A Phase Ib Study Evaluating Cobimetinib Plus Atezolizumab in Patients With Advanced BRAF V600 Wild-Type Melanoma Who Have Progressed During or After Treatment With Anti-PD-1 Therapy and Atezolizumab Monotherapy in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Dec 2022
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Cobimetinib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Roche
- 02 Nov 2022 Results(n=103, of cohorts A and B) assessing the efficacy and safety of cobimetinib plus atezolizumab in the treatment of patients with advanced BRAF(V600) wild type melanoma who had progressed on prior anti programmed death-1 therapy published in the European Journal of Cancer
- 30 Oct 2022 Results of pooled analysis form NCT03178851, NCT01689519, NCT02322814, and NCT02788279 of safety analysis, published in the Drug Safety
- 05 Oct 2020 Status changed from active, no longer recruiting to completed.